PIII Results within 6 Weeks !!!
Urocidin (Bladder cancer) PIII results in April 2010 .Urocidin has BLOCKBUSTER POTENTIAL (1-1,5 Billion Dollar Market Potential )
PIII RESULTS WILL BE POSITIVE ..MARK THIS POST !!!
Bioniche Life Science (BNC.TO) or (BNHLF.PK)
Market Cap: 86 Mio $
Cash: 30 Mio $
Price: 0,96 $
Bioniche Life Sciences Inc. (“Bioniche”; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating UrocidinTM in the treatment of bladder cancer. Recruitment has been completed in its Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy – Bacillus Calmette-Guérin (BCG).
The Data Monitoring Committee (DMC) held its ninth meeting regarding this clinical trial last week. After its meeting, the Committee has recommended that Bioniche “continue the trial unmodified until the next scheduled or triggered meeting.” The next scheduled meeting of the Committee is scheduled to occur in October.
Upcoming Milestones
2009/2010 Conditional license for E. coli cattle vaccine in the U.S.
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III NMI bladder cancer trial
2011 Belleville, ON vaccine manufacturing centre operational
AI
